Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials

• DOI: 10.1007/s10637-022-01321-8
• Publication Date: 2022-12-05T17:05:51Z
• Authors: Shigemasa Takamizawa; Yuki Katsuya; Yi-Ning Chen; Takaaki Mizuno; Takafumi Koyama; Kazuki Sudo; Tatsuya Yoshida; Shunsuke Kondo; Satoru Iwasa; Kan Yonemori; Toshio Shimizu; Noboru Yamamoto; Shigenobu Suzuki
• Keywords: Adult; Male; 0301 basic medicine; Brief Report; Incidence; Antineoplastic Agents; Drugs, Investigational; Middle Aged; 3. Good health; 03 medical and health sciences; Neoplasms; Toxic Optic Neuropathy; Humans; Female; Aged

Summary Ocular toxicities arising from anti-cancer drugs occur sporadically and are sometimes underestimated because they not life-threatening. Reports focusing on ocular cancer therapy limited. We investigated the detailed progress of including first-in-class ones. A retrospective review medical records was conducted for patients who were involved in early phase clinical trials with scheduled ophthalmologic examinations according to their protocols between January 2014 August 2021. Patients toxicity suspected be related investigational ophthalmic examination detail. In total, 37 occurred 7.6% (33/434). The median age 33 61 years (range, 33–76 years), 20 male. Causal a high incidence HSP90 inhibitors FGFR inhibitors. Retinopathy most frequent, while conjunctivitis, dry eye, keratitis, keratopathy, uveitis also observed. Dim vision as subjective finding unique adverse event. Most developed even though dose below drug’s maximum tolerated dose. Except one case, all bilaterally. About 60% (22/37) cases needed temporary hold drug. All except three fully recovered. This study reported risks timing onset variety drugs, which fundamentally controllable. (Trial registration number. Retrospectively registered)